Bart Hermans

Title: Bart Hermans: Innovator in Alzheimer's Disease Research

Introduction

Bart Hermans is a notable inventor based in Beerse, Belgium. He has made significant contributions to the field of Alzheimer's disease research, holding three patents that focus on innovative methods for diagnosis and treatment.

Latest Patents

Hermans' latest patents include groundbreaking methods for binding amyloid beta protein with pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments. This invention provides an antibody or antigen-binding fragment that binds to 3pE Aβ, along with methods for making and using these antibodies. The applications of this invention are crucial for the diagnosis, prognosis, and treatment of Alzheimer's disease and other β-amyloid-related diseases. Another significant patent involves methods for detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies, further emphasizing the importance of his work in this critical area of medical research.

Career Highlights

Bart Hermans is currently associated with Janssen Pharmaceutica NV, a leading pharmaceutical company. His work at Janssen has allowed him to focus on developing innovative solutions for complex health issues, particularly in neurodegenerative diseases.

Collaborations

Hermans collaborates with esteemed colleagues such as Marc Mercken and Bianca Van Broeck, who share his commitment to advancing research in Alzheimer's disease.

Conclusion

Bart Hermans is a prominent figure in the field of Alzheimer's research, with a focus on innovative methods for diagnosis and treatment. His contributions through patents and collaborations are paving the way for advancements in understanding and combating this challenging disease.